Functional MR: When to Intervene

Slides:



Advertisements
Similar presentations
Underwriting Impact of New Advances in Valvular Heart Disease NEHOUA 2012 Michael Clark, FACC, FLMI, FBIM Chief Medical Director Swiss Re.
Advertisements

CMR of Non-ischemic Dilated and Restrictive Cardiomyopathies
Perioperative Management of Heart Failure Gamal Fouad S Zaki, MD Professor of Anesthesiology Ain Shams University
Percutaneous Therapy of Pulmonic and Mitral Valve Disease Atman P. Shah MD FACC FSCAI Director, Coronary Care Unit Assistant Professor of Medicine The.
STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
The Influence of Radial vs. Femoral Access on Acute Blood Loss in Patients Undergoing Percutaneous Coronary Intervention Amit Nanda 1, Amit P. Amin 2,
Percutaneous mitral valve repair using the MitraClip® device (e-valve)
ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.
STICH Mitral Regurgitation Subanalysis Objective Examine the relationship of mitral regurgitation (MR) severity and survival and compare outcomes in patients.
Appendix: Clinical Guidelines VBWG. I Intervention is useful and effective III Intervention is not useful or effective and may be harmful A Data derived.
Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation Right Ventricular Function and Pulmonary Artery Hypertension After Degenerative.
AATS Grant Writing Workshop Developing a Clinical Research Program, Trial Design, Patient Enrollment Timothy J. Gardner MD Christiana Care Health System.
©2015 MFMER | Robotic Repair of Simple vs. Complex Degenerative Mitral Valve Disease Clinical and Echocardiographic Outcomes During Mid-Term.
Septal ablation in Hypertrophic Cardiomyopathy Charles Knight London Chest Hospital Advanced Angioplasty 2003.
Department of Surgery, University of Pennsylvania Health System Which Operation is Best for Severe Ischemic MR: Repair or Replace? Michael Acker William.
RALES: Randomized Aldactone Evaluation Study Purpose To determine whether the aldosterone antagonist spironolactone reduces mortality in patients with.
Impact of early surgery vs conventional treatment for infective endocarditis on mortality and embolic events: data from EASE trial Prospective RCT ( );
Athens Cardiology Update CADILLAC Study Blood Transfusion after Myocardial Infarction: Friend, Foe or double-edged Sword? Georgios I. Papaioannou,
Surgical outcome of native valve infective endocarditis in srinagarind hospital
BEST: Beta-blocker Evaluation Survival Trial Purpose To determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced.
SMMART-HF Surgery vs. Medical Treatment Alone for Patients with Significant MitrAl RegurgitaTion & Non-Ischemic Congestive Heart Failure Duke Heart Failure.
EVEREST II Study Design Multicenter Randomized in a 2:1 ratio to either percutaneous or conventional surgery for the repair or replacement of the mitral.
+ Mitral Valve Prolapse A Surgeon’s Perspective Charles Anderson, M.D. Saint Joseph’s Hospital of Atlanta.
2-Year Outcomes following Surgical Treatment of Moderate Ischemic Mitral Regurgitation: The Cardiothoracic Surgical Trials Network Robert E. Michler,
Asymptomatic mitral regurgitation When should you operate? Ben Bridgewater Cardiac surgeon and lead clinician, UHSM, Manchester Honorary Reader, Manchester.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Cardiovascular Surgery J Am Coll Cardiol.
Primary Mitral Regurgitation Degenerative Mitral Valve Disease
Outcomes in the CoreValve US High-Risk Pivotal Trial in Patients with a Society of Thoracic Surgeons Predicted Risk of Mortality Less than or Equal to.
Post-FDA Approval, Initial US Clinical Experience with Watchman Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation Vivek Y. Reddy.
Extending the Boundaries of TAVR: Future Directions
Role of Device Therapy in FMR: Challenges and Opportunities
李孟霖, 蔡函衿, 陳瑞雄, 侯紹敏 國泰綜合醫院 心臟血管外科
Jeff Macemon MBChB, PDMSM Advanced Trainee, CTS
on behalf of the EVEREST Investigators
Mitral Regurgitation: Epidemiology, Pathophysiology and When to Repair
University of Pennsylvania Philadelphia
Updates From NOTION: The First All-Comer TAVR Trial
TAVR-Endocarditis Tarek Chami, MD
Percutaneous Treatment for Functional Mitral Regurgitation Using The CARILLON ® Mitral Contour System™ Steven L. Goldberg, MD Director, Cardiac Cath.
The CARILLON: Device Iteration, New Data and New Trials
Revascularization in Patients With Left Ventricular Dysfunction:
TAVR in Patients with Chronic Lung Disease
TAVI Passed the Exam and is Ready for Clinical Use in Inoperable Patients Disclosures Research Funding and Speaking Honoraria: Edwards Lifesciences.
How I treat Functional Mitral Regurgitation: The Surgeon’s perspective
Surgical Mitral Valve Repair: What is the Gold Standard?
Clinical need for determination of vulnerable plaques
Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.
EVEREST II 5-Year Report and Beyond
Insights from the NCDR® STS/ACC TVT Registry.
Debate: What Does the Future Hold for the Treatment of Unprotected Left Main Disease? More PCI No More Routine Surgery Ron Waksman, MD, FACC Washington.
UNCERTAINTY OF RISK: THE CASE OF THE TRICUSPID DEVICES
James Hermiller, MD, FACC, FSCAI St Vincent Hospital, Indianapolis, IN
Niv Ad, MD Chief, Cardiac Surgery Inova Heart and Vascular Institute
S.G. Worthley, MB, BS, PhD., S. Redwood, MD, PhD.,
MitraClip: A Therapeutic Solution for Patients with Severe MR – Not a Candidate for Surgery Brij Maini MD, FACC Regional Medical Director of Transcatheter.
Fig. 3 Summary estimates of the relative risks for the different surgical techniques for late mortality. Comparing the two main techniques, EVR showed.
The Hidden Cost of Underutilizing PCI for Chronic Total Occlusions
Late Follow-Up from the PARTNER Aortic Valve-in-Valve Registry
Cardiovacular Research Technologies
Nishith Patel Waikato Cardiothoracic Unit
Samir R. Kapadia, MD On behalf of The PARTNER Trial Investigators
European Heart Association Journal 2007 April
Coronary Revascularization and TAVR
Zoll Firm Lecture Series
Maintenance of Long-Term Clinical Benefit with
Cardiovascular Epidemiology and Epidemiological Modelling
Operator Experience and Procedural Results of Transcatheter Mitral Valve Repair with Mitraclip: Insights from the STS/ACC TVT Registry Adnan K. Chhatriwalla,
Transcatheter versus medical treatment of symptomatic severe tricuspid regurgitation: a propensity score matched analysis Maurizio Taramasso MD, PhD from.
Presentation transcript:

Functional MR: When to Intervene Functional MR: When to Intervene? An Interventional Cardiologist’s Perspective. Marvin H. Eng M.D. Structural Heart Disease Fellowship Director Center for Structural Heart Disease

DISCLOSURES No financial disclosures

Functional MR Muscle is the 1° disease

Pathophysiology of CHF Positive Feedback Loop LV dysfunction MR

Prevalence of MR in US Population Functional MR US 319 million ~ 5.1 million IIIa Marchena E. et al. J Card Surg 2011;26:385-392.

Medically Treated Functional MR Prognosis Single center retrospective observational study showing the survival with respect to mortality and heart failure hospitalizations in mostly FMR patients. There was a small population of DMR. About 15% of the patients were observed to have improvements in their MR with medical therapy despite escalation. 2000-2008 Goel S et al. J Am Coll Cardiol 2014;63:185-6.

Survival in Cardiomyopathy Proportional to MR CHF Hospitalization Registry at 4 Italian Centers , excluded AV disease and MI. 1256 patients. KM plots showing mortality and CHF hospitalization for patients with FMR ischemic and non ischemic Survival ICM Survival NICM Rossi A. et al. Heart 2011;97:1675-1680.

Improved Outcomes with (DMR) Intervention Early in Natural History 229 patents with flail leaflets 1980-1989 and the found that survival was worse when NYHA functional class was more advanced. Patients clearly did better with early surgery and with milder symptoms Ling LH et al. Circulation 1997;96:875-883.

Early corrective surgery (DMR) Minimizes heart failure risk Suri RM et al. JAMA 2013;310:609-616.

Advanced Symptoms Portend Poorer Prognosis in Surgery STS Database 1991-2007 % operative mortality STS database 1991-2007 Linked STS and CMS records 77,667 operations, after exclusions 14,604 operations Badhwar V. et al. Ann Thorac Surg 2012;94:1870-9.

Mitral valve surgery

MV Annuloplasty Lack of Efficacy in Functional MR Medical Medical Censoring pts with CAD All comers Surgery Surgery 199-2002 LVEF <= 30% and moderate-severe MR. Pts had mitral annuloplasty N=126 Wu AH et al. J Am Coll Cardiol 2005;45:381-7.

Repair in Functional MR (Ischemic) Prone to Recurrent MR Goldstein D et al. N Engl J Med 2016;374:344-53.

Recurrent MR Portends Worse Long-Term Prognosis 133 patients with recurrent MR Median 3.7 yrs (1.1-7.6) Multivariate analysis for Mortality MR recurrence 1.72 HR (1.24-2.39) p=0.002 Isolated degenerative MR repair N=1218 patients Mayo series 1990-2000 Suri RM et al. J Am Coll Cardiol 2016;67:488-98.

Mitral Valve Replacement in ICM Higher Early Mortality Compared to Repair Acker MA et al. N Engl J Med 2014;370:23-32.

Frailty Impacts mortality and independence Lee DH et al. Circulation 2010;121:973-978.

Percutaneous Treatment FMR

COAPT MR reduction and symptom relief 1+ 2+ N=24 N=36 Stone GW et al. TCT 2016

Meta-Analysis LV remodeling with Mitra-Clip Meta-analysis mitral clip in FMR 9 studies; Follow up 6-12 months (9 months) D’ascenzo F. et al. Am J Cardiol 2015;116:325-331.

Functional MR Clip vs. OMT Survival Hospitalizations 120 patient trial and survival and decreased hospitalizations seen in treated patients. Patients eligible for Clip underwent the procedure and all others were managed with medicines. Giannini C. et al. Am J Cardiol 2016;117:271-277.

FMR Data 1 Yr data across studies OMT OMT

ACCESS-EU FMR Survival Related to Baseline LVEF Schafer U et al. Am J Cardiol 2016;118:873-880.

Post Mitra-Clip NYHA I/II, MR ≤ 2+ do better Kar S TCT 2016

TCVT-Mitral Clip Acute Procedural Complications FMR % Transcatehter Valve Treatment Sentinel Registry or Eurobservation Research Programme. 8 centers 2011-2012. 72% pts with FMR. Pighi M et al. Am J Cardiol (in press)

Summary Functional mitral regurgitation Valve therapy has potential to mitigate progression Historically early treatment of MR improves outcomes Surgical treatment Replacement high early mortality Repair high rates of recurrent MR Percutaneous Mitral clip Lower early morbidity and mortality Appears to have survival benefit Treatment Early in Disease Process is Key Select anatomic candidates with a high chance for success More therapies on the horizon

Mitra-Clip in FMR NICM/ICM Survival Pighi M et al. Am J Cardiol (in press)

Mitra-Clip in FMR NICM/ICM Hospitalization for CHF Pighi M et al. Am J Cardiol (in press)

Mitra-Clip in NICM/ICM Similar Reductions in MR Pighi M et al. Am J Cardiol (in press)

COAPT Roll-in Data N=50 Stone GW et al. TCT 2016

Mitral Clip in FMR Comparison to Surgery Mauri L et al. JACC 2013;62:317-28.

TCVT-European Registry DMR/FMR Survival Nickenig G et al. J Am Coll Cardiol 2014;64:875-84.

TCVT DMR/FMR CHF Hospitalization Nickenig G et al. J Am Coll Cardiol 2014;64:875-84.

Surgical Repair with DCM Cardiomyopathy therapy 54 DCM patients s/p repair for FMR; 2000-2011 De Bonis M et al. Eur J Cardio-Thoracic Surg 2012;42:640-646.

ACCESS-EU MR reduction least with lowest LVEF FMR patients from ACCESS EU; 69.3% FMR Schafer U et al. Am J Cardiol 2016;118:873-880.